findmyKOL

Allison Kwong, MD

Basic profile

Palo Alto University

ORCIDNPI
RegionStanford, CA · WestSpecialtyGastroenterologyFocusGastroenterology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH funding2021–2025

Allison Kwong is a Gastroenterology physician affiliated with Palo Alto University. OpenAlex indexes 178 publications with 3,734 citations (h-index 24).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
178publications

Distinct works indexed by OpenAlex, matched via ORCID.

3,734citations

Total citations across indexed works.

24h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2021–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

300 Pasteur Dr
Stanford, CA 943052200

Telephone

650-723-4000

Provider last certified this registry record 25 Apr 2024.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    36.2%
    Beta blocker11.1%
    Propranolol Hcl68%Carvedilol32%
    Part D<11 patients
    Loop diuretic11.1%
    Furosemide100%
    Part D14 patients

    + 3 more classes in this area

  • Anti-infectives

    22.1%
    Nucleoside and nucleotide reverse transcriptase inhibitors12.2%
    Vemlidy69%Tenofovir Disoproxil Fumarate31%
    Part D<11 patients
    Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor6.6%
    Entecavir100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    18.1%
    Rifamycin Antibacterial8%
    Xifaxan100%
    Part D<11 patients
    Proton pump inhibitor7.1%
    Pantoprazole Sodium100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)68.6% facility · 31.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20212025 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”